innate
pharma
launches
hopeconnectlearn
new
online
resource
hairy
cell
leukemia
patients
rockville
globe
newswire
innate
pharma
sa
euronext
paris
iph
isin
nasdaq
ipha
innate
company
today
announced
launch
hopeconnectlearn
new
online
resource
hairy
cell
leukemia
community
hopeconnectlearn
provides
education
connection
patients
caregivers
across
spectrum
disease
new
diagnosis
relapse
refractory
experiences
hopeconnectlearn
includes
website
social
media
channels
patients
caregivers
find
information
rare
disease
tools
help
empower
patients
conversations
physician
well
patient
stories
hairy
cell
leukemia
diagnosis
relapse
refractory
experience
daunting
patients
connection
others
navigating
similar
challenges
provide
needed
comfort
strength
said
jennifer
butler
executive
vice
president
general
manager
innate
pharma
us
hopeconnectlearn
provides
community
patients
connect
learn
others
experience
matter
journey
hairy
cell
leukemia
rare
blood
cancer
accounting
two
three
percent
cases
adult
leukemias
approximately
new
cases
diagnosed
disease
affects
men
women
occurs
commonly
older
adults
name
stems
thin
projections
found
surface
abnormal
white
blood
cells
indicate
disease
often
slow
growing
indolent
form
cancer
percent
patients
normal
life
expectancy
percent
patients
relapse
years
following
first
facing
rare
disease
like
hairy
cell
leukemia
patients
derive
hope
hearing
directly
patients
learning
experiences
said
anna
lambertson
executive
director
hairy
cell
leukemia
foundation
important
patients
caregivers
across
spectrum
disease
know
alone
join
hopeconnectlearn
community
online
twitter
hopeconnectlrn
instagram
hopeconnectlearn
hopeconnectlearn
innate
pharma
innate
pharma
commercial
stage
biotech
company
dedicated
improving
treatment
clinical
outcomes
patients
therapeutic
antibodies
harness
immune
system
fight
cancer
innate
pharma
broad
pipeline
antibodies
includes
several
potentially
clinical
preclinical
candidates
cancers
high
unmet
medical
need
innate
pharma
pioneer
understanding
natural
killer
cell
biology
expanded
expertise
tumor
microenvironment
well
antibody
engineering
innovative
approach
resulted
diversified
proprietary
portfolio
major
alliances
leaders
biopharmaceutical
industry
including
squibb
novo
nordisk
sanofi
collaboration
astrazeneca
based
marseille
france
innate
pharma
listed
euronext
paris
nasdaq
us
learn
innate
pharma
information
innate
pharma
shares
isin
code
ticker
code
lei
euronext
iph
nasdaq
ipha
additional
information
please
contact
investors
innate
pharma
tel
investors
media
innate
pharma
tracy
rossin
global
us
tel
disclaimer
information
risk
factors
press
release
contains
certain
statements
including
within
meaning
private
securities
litigation
reform
act
use
certain
words
including
believe
potential
expect
similar
expressions
intended
identify
statements
although
company
believes
expectations
based
reasonable
assumptions
statements
subject
numerous
risks
uncertainties
could
cause
actual
results
differ
materially
anticipated
risks
uncertainties
include
among
things
uncertainties
inherent
research
development
including
related
safety
progression
results
ongoing
planned
clinical
trials
preclinical
studies
review
approvals
regulatory
authorities
product
candidates
company
commercialization
efforts
company
continued
ability
raise
capital
fund
development
overall
impact
outbreak
global
healthcare
system
well
company
business
financial
condition
results
operations
additional
discussion
risks
uncertainties
could
cause
company
actual
results
financial
condition
performance
achievements
differ
contained
statements
please
refer
risk
factors
facteurs
de
risque
section
universal
registration
document
filed
french
financial
markets
authority
amf
available
amf
website
http
innate
pharma
website
public
filings
reports
filed
securities
exchange
commission
sec
including
company
annual
report
form
year
ended
december
subsequent
filings
reports
filed
amf
sec
otherwise
made
public
company
press
release
information
contained
herein
constitute
offer
sell
solicitation
offer
buy
subscribe
shares
innate
pharma
country
ja
current
emerging
treatment
options
hairy
cell
leukemia
onco
targets
ther
ii
troussard
x
cornet
hairy
cell
leukemia
update
diagnosis
treatment
j
hematol
iii
teras
lr
desantis
ce
cerhan
jr
morton
lm
jemal
flowers
cr
us
lymphoid
malignancy
statistics
world
health
organization
subtypes
ca
cancer
j
clin
iv
grever
mr
blachly
js
andritsos
la
hairy
cell
leukemia
update
molecular
profiling
therapeutic
advances
blood
rev
